Lexicon Pharmaceuticals Unveils Key Insights on DPNP

Lexicon Pharmaceuticals to Showcase DPNP Findings

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is set to present important patient-reported data regarding diabetic peripheral neuropathic pain (DPNP) at an upcoming meeting of the American Society of Pain and Neuroscience. This meeting aims to shed light on the impact of DPNP, a condition that has often been overlooked.

Understanding Diabetic Peripheral Neuropathic Pain

DPNP is a serious and chronic condition affecting individuals with diabetes. This condition manifests through a variety of symptoms including burning pain, numbness, and other distressing sensations primarily in the limbs. Currently, around nine million people in the United States are living with DPNP, which affects a substantial percentage of those with diabetes—30% of type 1 and 50% of type 2 diabetes patients.

The Patient Experience Matters

In an effort to bring attention to the patient experience, Dr. M. Belinda Hardin from Lexicon Pharmaceuticals emphasizes the importance of understanding how DPNP affects daily activities for nearly 100 million people globally. The aim is not just to raise awareness among health care providers but also to empower patients and caregivers in discussing treatment options with medical professionals.

Presentation Schedule

Details of the presentation are as follows: "Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin" — on Saturday, 9:40-10:00 a.m. ET, Poster #125 at the Sparkle Ballroom, presented by Dr. Hardin from the U.S. Medical Affairs team at Lexicon Pharmaceuticals.

Pilavapadin: An Innovative Approach to Pain Management

Lexicon Pharmaceuticals has been at the forefront of drug discovery with Pilavapadin (LX9211), which represents a novel small molecule indicating promise in treating neuropathic pain. By targeting AAK1, an innovative pathway for neuropathic pain mechanisms, Pilavapadin operates by influencing neurotransmitter activity without engaging opioid pathways. This approach marks a significant step toward safer alternatives for pain management in patients.

Clinical Development and Research Findings

The efficacy and safety of Pilavapadin were evaluated in the Phase 2a proof-of-concept RELIEF-DPN-1 study. This study achieved its primary objective by demonstrating a significant reduction in average daily pain scores after six weeks compared to a placebo, showcasing noteworthy benefits in alleviating symptoms of DPNP, specifically burning pain and sleep disturbances. Additionally, Pilavapadin has earned Fast Track designation from the U.S. Food and Drug Administration, which bodes well for its clinical development trajectory.

About Lexicon Pharmaceuticals

Lexicon is dedicated to pioneering transformative medicines aimed at enhancing patient quality of life. Through its Genome5000™ program, the company successfully engages in meticulous genomics research to identify essential protein targets with potential therapeutic applications across various diseases. Their pipeline includes several promising candidates in neuropathic pain, metabolic disorders, and more.

Connect with Lexicon Pharmaceuticals

For more information, investors and interested parties can reach out to Lisa DeFrancesco at Lexicon Pharmaceuticals, Inc. at lexinvest@lexpharma.com.

Frequently Asked Questions

What is DPNP?

Diabetic peripheral neuropathic pain (DPNP) is a chronic and painful condition affecting people with diabetes, characterized by symptoms like burning and numbness in extremities.

What is Lexicon Pharmaceuticals focusing on at the ASPN meeting?

Lexicon Pharmaceuticals will present patient-reported data regarding the impacts of DPNP, aiming to enhance awareness and understanding among healthcare providers.

What is Pilavapadin's mechanism of action?

Pilavapadin is an investigational drug that selectively inhibits AAK1, which plays a role in neuropathic pain while avoiding opioid pathways, potentially leading to fewer side effects.

How can patients learn more about clinical trials?

Patients interested in learning about ongoing trials can contact Lexicon or consult their healthcare providers to explore available options.

What is the significance of the Fast Track designation for Pilavapadin?

The Fast Track designation accelerates the development process of Pilavapadin, facilitating quicker access to market for patients who suffer from DPNP.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.